United Therapeutics generates 41% net margins and ranks best-in-class on margins among specialty pharmaceutical peers, but severe product concentration where Tyvaso DPI and Nebulized Tyvaso together account for 59% of revenue, combined with 3 earnings misses in 4 quarters, makes the current risk profile unfavorable for new positions.
Thesis pillars
- Best In Class Pharma Margins→Stable
- Product Concentration Tyvaso↑Improving
- Earnings Miss Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 25, 2026· older than 90 days
United Therapeutics Corporation (UTHR) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $608.49, A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty.
United Therapeutics markets five therapies for pulmonary arterial hypertension and rare diseases — Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Unituxin — generating approximately $3.16 billion in total revenues in 2025. Tyvaso DPI and Nebulized Tyvaso together... Read more
Sell if holding. At $608.49, A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news boost analyst 0.60, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: moderate.
Recent developments
updated Nov 4, 2026Recent Developments — United Therapeutics Corporation
Latest news
- NEWS United Therapeutics Announces Acquisition of Pfizer Royalty Interest in Ralinepag — fiscal.ai Nov 4, 2026 positive
- NEWS United Therapeutics(UTHR.US) Officer Sells US$5.58 Million in Common Stock - Moomoo — Moomoo Oct 28, 2026 negative
- NEWS UTHR Maintains Rating by JP Morgan -- Price Target Lowered to $6 - GuruFocus — GuruFocus Oct 28, 2026 negative
- NEWS United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS $100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga — Benzinga Oct 28, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:54:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTyvaso DPI and Nebulized Tyvaso59%10-K Item 1: 'combined Tyvaso DPI and Nebulized Tyvaso net product sales, representing 59 percent...of our total revenues for the years ended December 31, 2025'
- HIGHCustomerAccredo and CVS Specialty10-K Item 1A: 'we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty'
- HIGHSupplierMannKind Corporation10-K Item 1A: 'We rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us, with no plans to develop an alternate or backup supply arrangement'
- HIGHSupplierDEKA10-K Item 1A: 'We rely entirely on DEKA and its affiliates to manufacture the Remunity and RemunityPRO Pumps'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Revenue shrinking — -1.9% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $608.49, A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $573.85. Score 5.4/10, moderate confidence.
Analyst target $583.71 reached (−4.1% from $608.49); no take-profit level is published. Prior stop was $573.85. Stop-loss: $573.85.
Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Customer: Accredo and CVS Specialty; Analyst target reached - limited upside remaining.
United Therapeutics Corporation trades at a P/E of 23.0 (forward 18.0). TrendMatrix value score: 4.8/10. Verdict: Sell.
22 analysts rate UTHR, with a consensus score of 4.1/5. 14 analysts publish price targets averaging $671.
What does United Therapeutics Corporation do?United Therapeutics markets five therapies for pulmonary arterial hypertension and rare diseases — Tyvaso DPI,...
United Therapeutics markets five therapies for pulmonary arterial hypertension and rare diseases — Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, and Unituxin — generating approximately $3.16 billion in total revenues in 2025. Tyvaso DPI and Nebulized Tyvaso together accounted for 59% of revenues; substantially all treprostinil revenues flow through two distributors, Accredo and CVS Specialty, with no FDA-approved backup manufacturing site for Orenitram or Unituxin.